Zahlen Protein!!! - 500 Beiträge pro Seite

[PeweHoffi]

Ich weiß, ich weiß, es nervt!!

Von einem Kollegen habe ich gerade erfahren, daß irgend ein
User schon etwas von den Quartalszahlen in Erfahrung gebracht hat! Leider erreiche ich ihn nicht mehr, somit finde ich denn dann auch den Thread nicht, wo diese Meldung gepostet wurde!
Solltest DU, netter User, noch online sein, so poste deine Daten doch noch mal in diesen Thread rein, um sie allen Mitaktionären zur Verfügung zu stellen!!!!!!!!!!!!!!!!!!!!

Entschuldigenderweise untertänigst für die Nerverei

PeweHoffi

[whoracle]

FREMONT, Calif., Aug 1 /PRNewswire/ -- Protein Design Labs, Inc. (PDL) (Nasdaq: PDLI - news) today reported revenues of $20.4 million and net income of $5.0 million, or $0.25 per basic share and $0.23 per diluted share, for the three months ended June 30, 2000. These results compare with revenues of $8.3 million and a net loss of $2.7 million, or ($0.14) per basic and diluted share, in the 1999 second quarter. In the 2000 first quarter PDL had revenues of $15.5 million and net income of $770,000, or $0.04 per basic and diluted share.

Revenues under agreements with third parties increased to $15.9 million in the quarter ended June 30, 2000, compared with $6.0 million in the 1999 second quarter. Revenues in the 2000 second quarter included royalty revenues from first quarter 2000 sales of three products licensed under PDL`s antibody humanization patents: Synagis® (palivizumab) from MedImmune, Inc., Herceptin® (trastuzumab) from Genentech, Inc. and Zenapax® (daclizumab) from Hoffmann-La Roche Inc. Other components of revenue included up-front fees paid to PDL pursuant to patent license agreements, a portion of up-front fees paid to PDL pursuant to humanization agreements, license maintenance payments, sponsored research and development funding, and interest income.

Total costs and expenses in the 2000 second quarter were $15.3 million, compared with $11.0 million in the second quarter of 1999. Research and development expenses were $10.2 million in the second quarter of 2000, compared with $8.5 million in the year-earlier period. General and administrative expenses were $2.9 million and $2.4 million in the 2000 and 1999 second quarters, respectively. Interest expense was $2.3 million in the 2000 second quarter compared with none in the second quarter of 1999.

Revenues during the first six months of 2000 totaled $35.9 million, compared with $17.1 million in the first six months of 1999. PDL had net income of $5.8 million, or $0.30 per basic share and $0.27 per diluted share, in the first six months of 2000, compared with a net loss of $4.6 million, or ($0.25) per basic and diluted share, in the first six months of 1999.

At June 30, 2000, PDL had cash, cash equivalents and investments totaling $309.9 million, compared with $137.2 million at December 31, 1999. The increase in our cash position was due primarily to the private placement in February 2000 of $150 million in principal amount of 5.5% convertible subordinated notes due 2007.

PDL`s revenues for the first half of 2000 exceeded our revenues for all of 1999. This revenue growth reflects the increasing total sales of humanized monoclonal antibodies which utilize PDL`s technology. In May American Home Products launched a fourth licensed antibody product, Mylotarg(TM). Multiple additional humanized antibodies are in late stage clinical trials or pending regulatory approval.

PDL`s revenues have varied in the past and will likely continue to fluctuate considerably from quarter to quarter and from year to year. As a result, our revenues in any period may not be predictive of revenues in any subsequent period. Our royalty revenues may be unpredictable and may fluctuate since they depend upon the seasonality of sales of licensed products, the existence of competing products, the marketing efforts of our licensees, potential reductions in royalties payable to us due to credits for prior payments to us, the timing of royalty reports, some of which are required quarterly and others semi-annually, our method of accounting for royalty revenues from our licensees and our ability to successfully defend and enforce our patents. Other revenue may also be unpredictable and may fluctuate due to the timing of payments of non-recurring licensing and signing fees and payments for manufacturing services and achievement of milestones under new and existing collaborative, humanization, and patent licensing agreements. Revenue historically recognized under our prior agreements may not be an indicator of revenue from any future collaborations.

PDL has recognized revenue during the quarter and six months ended June 30, 2000, in accordance with its historical practice. In December 1999, the Securities and Exchange Commission issued Staff Accounting Bulletin No. 101, ``Revenue Recognition in Financial Statements`` (SAB 101). We are evaluating the effects, if any, that SAB 101 and the adoption of SAB 101 in the fourth quarter of 2000, effective January 1, 2000, may have on the results of our operations or our financial position. We have been advised that the Securities and Exchange Commission intends to provide guidance during the third quarter of 2000 with respect to the interpretation of SAB 101. It is unknown whether such guidance will require companies, including PDL, to alter revenue recognition practices or to restate revenues for the first or second quarter of 2000.

Protein Design Labs is a leader in the development of humanized antibodies to prevent or treat various disease conditions. PDL currently has antibodies under development for autoimmune and inflammatory conditions, transplantation, cancer and other conditions. PDL holds fundamental patents in the U.S., Europe and Japan for its antibody humanization technology. Further information on PDL is available through the Company`s website at www.pdl.com.

NOTE: Protein Design Labs and the PDL logo are registered U.S. trademarks of Protein Design Labs, Inc. Zenapax is a registered U.S. trademark of Hoffmann-La Roche Inc. Synagis is a registered U.S. trademark of MedImmune, Inc. Herceptin is a registered U.S. trademark of Genentech, Inc. Mylotarg is a trademark of American Home Products Corporation.


PROTEIN DESIGN LABS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)

[mando]

Ist doch super: Q2 Earns 23 cents vs. loss 14 cents yr ago QTR
Schönen Abend, mando

[PeweHoffi]

@whoracle

Besten Dank für die Zahlen, das hilft weiter!!!!!!!!!!!!!!!!!!!!!!
Liebe Grüße!!

[whoracle]

@mando
Ich glaube das siehst Du falsch. es ist ein Verlust von 0.23$ pro Aktie.


Three months ended Six months ended
June 30, June 30,
2000 1999 2000 1999
Revenues:
Revenue under agreements
with third parties $15,893 $6,039 $28,343 $12,501
Interest and other
income 4,472 2,249 7,521 4,623
Total revenues 20,365 8,288 35,864 17,124
Costs and expenses:
Research and development 10,216 8,513 21,284 16,793
General and administrative 2,870 2,450 5,329 4,895
Interest expense 2,257 -- 3,460 --
Total costs and
expenses 15,343 10,963 30,073 21,688
Net income (loss) $5,022 $(2,675) $5,791 $(4,564)
Net income (loss)
per share:
Basic $0.25 $ (0.14) $ 0.30 $ (0.25)
Diluted $0.23 $(0.14) $0.27 $(0.25)

Weighted average number
of shares:
Basic 19,757 18,625 19,609 18,622
Diluted 21,631 18,625 21,593 18,622

Der Verlust wurde aber erwartet und ist bereits im Kurs eingepreist.
Die Umsätze konnten im Vergleich zum vorjahr fast verdreifacht werden.
Der Kurs steigt nachbörslich auf jetzt ... wow ... 139,5$ !!!

whoracle

[Pitu]

0,23 gewinn

[whoracle]

Sicher???
Warum steht dann bei Net income ein "Loss" in Klammern?
whoracle

[RYM]

Wo hast du denn den nachbörslichen Kurs her????

[whoracle]

@RYM

www.island.com
BookViewer starten, und Kürzel (PDLI) eingeben

whoracle

[RYM]

Danke!!!!!!!!!!

[Pitu]

@whoracle
die zahl in klammer ist die des vorigen quartals